South Korea�s Hanmi Pharmaceutical $HANPF signed an exclusive development and license agreement with Roche�s Genentech $RHHBY to develop and commercialize Hanmi�s pan-RAF inhibitor, Phase 1 clinical trial, HM95573. According to the terms of the agreement, Hanmi will receive an upfront fee of $80mn, $830mn in milestones, and tiered double-digit royalties on net sales.